Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
DSGN Stock Chart & Stats
$8.94
-$0.66(-11.15%)
At close: 4:00 PM EST
$8.94
-$0.66(-11.15%)
Day’s Range― - ―
52-Week Range$2.60 - $11.23
Previous CloseN/A
Volume97.34K
Average Volume (3M)213.56K
Market Cap
$635.84M
Enterprise Value$571.09M
Total Cash (Recent Filing)$219.84M
Total Debt (Recent Filing)$645.00K
Price to Earnings (P/E)―
Beta1.28
Next Earnings
May 11, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding61,672,280
10 Day Avg. Volume267,018
30 Day Avg. Volume213,565
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.53
Price to Sales (P/S)0.00
P/FCF Ratio-9.86
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.59K
Enterprise Value/Ebitda-7.24
Forecast
1Y Price Target
$15.50Price Target Upside73.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Formulation Improves Systemic DeliveryAnalyst notes the DT-216P2 formulation uses the same active drug but substantially improves systemic delivery compared with the earlier version, addressing a principal limitation that constrained prior efficacy.
Modeling Supports Stronger Biomarker ResponseAnalyst's pharmacokinetic and pharmacodynamic modeling indicates the improved delivery is likely to translate into larger frataxin increases, which de-risks the expected clinical signal and supports upside if a meaningful biomarker response is observed.
Platform Safety And Dosing FlexibilityAnalyst highlights that the GeneTAC platform modulates gene expression without permanently altering DNA and supports convenient dosing formats such as injections or oral pills, a combination that may reduce safety concerns and broaden patient access.
Bears Say
Clinical Trial And Regulatory Risk If Biomarkers Do Not TranslateAnalyst indicates that transient or modest frataxin changes may fail to translate into meaningful clinical endpoints, increasing the risk of negative trial outcomes or regulatory setbacks.
Dependence Of Benefit On Achieved Drug ConcentrationAnalyst warns prior benefits were tied to drug levels, so insufficient systemic drug concentrations in patients could limit therapeutic effect even with the new formulation.
Durability Of Biomarker ResponseAnalyst cautions that the earlier formulation produced only temporary frataxin increases, raising concern that observed biomarker gains might not be sustained long enough to provide lasting clinical benefit.
Design Therapeutics News
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $2.60 and its highest was $11.23 in the past 12 months.
What is Design Therapeutics’s market cap?
Design Therapeutics’s market cap is $635.84M.
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is May 11, 2026 which is in 49 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on Mar 09, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.354 by $0.084.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Undervalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 61,672,280 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.354. Following the earnings report the stock price went down -3.664%.
Which hedge fund is a major shareholder of Design Therapeutics?
Currently, no hedge funds are holding shares in DSGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Design Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (73.38% Upside)
$15.50 (73.38% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.65%
12-Months-Change
Fundamentals
Return on Equity
-32.72%
Trailing 12-Months
Asset Growth
-10.05%
Trailing 12-Months
Company Description
Design Therapeutics
Design Therapeutics (DSGN) is a biotechnology company focused on developing novel therapies for serious degenerative diseases caused by nucleotide repeat expansions. The company operates within the pharmaceutical and biotechnology sectors, leveraging its GeneTAC platform to design small-molecule treatments that target the underlying genetic causes of these diseases. Design Therapeutics aims to address unmet medical needs in conditions such as Friedreich ataxia and other similar genetic disorders.
DSGN Stock 12 Month Forecast
Average Price Target
$15.50
▲(73.38% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
17.10% Insiders
5.61% Mutual Funds
33.58% Other Institutional Investors
38.11% Public Companies and
Individual Investors